Daily Oncology News

Erivedge Approved to Treat Basal Cell Carinoma

January 31, 2012

Erivedge (vismodegib) has been approved by the U.S. Food and Drug Administration to treat the most common form of skin cancer, basal cell carcinoma, the agency said Monday.
 

Antiretroviral Medications Linked to Cleft Deformities

January 31, 2012

Drugs to keep HIV-infected women from transmitting virus to fetus may trigger cleft defects.
 

Education Reduces Distress During Breast Cancer Treatment

January 31, 2012

Physical, emotional, and social adjustment occurs over time with or without interventions
 

Drug Approved for Advanced Kidney Cancer

January 27, 2012

Inlyta has been approved by the FDA to treat advanced renal cell carcinoma in patients who haven't responded to another drug.
 

Comparable Clinical Activity for Low-, High-Dose Clofarabine

January 27, 2012

More adverse effects seen for high dose in patients with higher-risk myelodysplastic syndrome
 

Polypectomy Outcomes Similar to Surgical Resection

January 27, 2012

For management of malignant colonic polyps in patients with comparable clinical characteristics
 

New PCR-Based Assay Better Predicts Lung Cancer Survival

January 27, 2012

Assay identifies which early-stage NSCLC patients are at high risk of death after surgical resection
 

Not Enough Americans Being Screened for Cancer

January 26, 2012

Rates of cancer screening in the United States are short of Healthy People 2020 targets for breast, cervical, and colorectal cancer screening
 

Radiation Benefits Mixed After Breast-Preserving Surgery

January 26, 2012

Radiation therapy slightly improves survival, but may increase likelihood of eventual mastectomy.
 

Survival Reduced for Patients With Cancer Who Have Diabetes

January 26, 2012

Type of cancer and diabetes treatment influence survival, according to a recent study.
 
 Subscribe to the RSS for this page  [view all our RSS feeds here]

Web Exclusives

Psychosocial approach useful in managing cancer pain

February 03, 2012

Psychosocial interventions, including skills instruction and education, can help reduce pain in persons with cancer, confirm the results of a recent meta-analysis.
 

Experimental agent slows progression of colorectal cancer

February 02, 2012

The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.
 

In HER2 breast cancer, lapatinib works better with trastuzumab than without

February 01, 2012

Lapatinib is not as effective as trastuzumab against (HER2)-positive breast cancer, but combining the two nearly doubles the effectiveness seen with either one alone.
 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions